Literature DB >> 16299308

Regulation of cellular caveolin-1 protein expression in murine macrophages by microbial products.

Mei G Lei1, Xiaoyu Tan, Nilofer Qureshi, David C Morrison.   

Abstract

Previously, we reported that expression of caveolin-1 in elicited peritoneal mouse macrophages was up-regulated by remarkably low (1.0-pg/ml) concentrations of Escherichia coli O111 lipopolysaccharide (LPS). Here we report that increases in caveolin-1 expression are manifested by different types of LPS, LPS-mimetic taxol, and heat-killed E. coli and to a much lesser extent by zymosan, polysaccharide-peptidoglycan, and heat-killed Staphylococcus aureus. Rhodobacter sphaeroides lipid A (RsDPLA) could not induce caveolin-1 expression in macrophages. Interestingly, polymyxin B (5 microg/ml) and RsDPLA show only a limited capacity to inhibit LPS-induced caveolin-1 expression. These findings suggest that expression of caveolin-1 in response to LPS may only partially be dependent upon lipid A. Recombinant tumor necrosis factor alpha marginally induces caveolin-1, suggesting that the ability of LPS to regulate caveolin-1 is not mediated primarily through an autocrine/paracrine mechanism involving this cytokine. Under conditions in which cellular levels of caveolin-1 are profoundly induced, no significant changes in TLR4 expression are observed. Of interest, caveolin-1 appears to localize to two cellular compartments, one associated with lipid rafts and a second associated with TLR4. Gamma interferon treatment inhibits the induction of caveolin-1 by LPS in macrophages. Inhibition of the p38 kinase-dependent pathway, but not the extracellular signal-regulated kinase pathway, effectively reduced the ability of LPS to mediate caveolin-1 up-regulation. Lactacystin, a potent inhibitor of the proteasome pathway, significantly modulates LPS-independent caveolin-1 expression, and lactacystin inhibits LPS-triggered caveolin-1 responses. These studies suggest that caveolin-1 up-regulation in response to LPS is likely to be proteasome dependent and triggered through the p38 kinase pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299308      PMCID: PMC1307083          DOI: 10.1128/IAI.73.12.8136-8143.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Caveolin, a protein component of caveolae membrane coats.

Authors:  K G Rothberg; J E Heuser; W C Donzell; Y S Ying; J R Glenney; R G Anderson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

2.  Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts.

Authors:  J R Glenney; D Soppet
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

Review 3.  Endotoxins and disease mechanisms.

Authors:  D C Morrison; J L Ryan
Journal:  Annu Rev Med       Date:  1987       Impact factor: 13.739

4.  Chemical reduction of 3-oxo and unsaturated groups in fatty acids of diphosphoryl lipid A from the lipopolysaccharide of Rhodopseudomonas sphaeroides. Comparison of biological properties before and after reduction.

Authors:  N Qureshi; K Takayama; K C Meyer; T N Kirkland; C A Bush; L Chen; R Wang; R J Cotter
Journal:  J Biol Chem       Date:  1991-04-05       Impact factor: 5.157

5.  The role of IFN-gamma in the pathology of experimental endotoxemia.

Authors:  F P Heinzel
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

6.  Complete structural determination of lipopolysaccharide obtained from deep rough mutant of Escherichia coli. Purification by high performance liquid chromatography and direct analysis by plasma desorption mass spectrometry.

Authors:  N Qureshi; K Takayama; P Mascagni; J Honovich; R Wong; R J Cotter
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

7.  Rhodopseudomonas sphaeroides lipid A derivatives block in vitro induction of tumor necrosis factor and endotoxin tolerance by smooth lipopolysaccharide and monophosphoryl lipid A.

Authors:  B E Henricson; P Y Perera; N Qureshi; K Takayama; S N Vogel
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

8.  Diphosphoryl lipid A obtained from the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides is an endotoxin antagonist in mice.

Authors:  N Qureshi; K Takayama; R Kurtz
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

9.  Shared actions of endotoxin and taxol on TNF receptors and TNF release.

Authors:  A H Ding; F Porteu; E Sanchez; C F Nathan
Journal:  Science       Date:  1990-04-20       Impact factor: 47.728

10.  Lipopolysaccharide-induced selective priming effects on tumor necrosis factor alpha and nitric oxide production in mouse peritoneal macrophages.

Authors:  X Zhang; D C Morrison
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  15 in total

1.  Caveolin-1 protects against sepsis by modulating inflammatory response, alleviating bacterial burden, and suppressing thymocyte apoptosis.

Authors:  Hong Feng; Ling Guo; Zhiqing Song; Haiqing Gao; Dan Wang; Weisi Fu; Jingyan Han; Zhenyu Li; Bin Huang; Xiang-An Li
Journal:  J Biol Chem       Date:  2010-06-09       Impact factor: 5.157

2.  Caveolin-2-deficient mice show increased sensitivity to endotoxemia.

Authors:  Cecilia J de Almeida; Agnieszka K Witkiewicz; Jean-François Jasmin; Herbert B Tanowitz; Federica Sotgia; Philippe G Frank; Michael P Lisanti
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

3.  HIV infection upregulates caveolin 1 expression to restrict virus production.

Authors:  Shanshan Lin; Xiao Mei Wang; Peter E Nadeau; Ayalew Mergia
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

4.  Role of Caveolin Proteins in Sepsis.

Authors:  Grzegorz Sowa
Journal:  Pediatr Ther       Date:  2012-01-12

5.  Study of caveolin-1 gene expression in whole adipose tissue and its subfractions and during differentiation of human adipocytes.

Authors:  José M Fernández-Real; Victoria Catalán; José M Moreno-Navarrete; Javier Gómez-Ambrosi; Francisco J Ortega; Jose I Rodriguez-Hermosa; Wifredo Ricart; Gema Frühbeck
Journal:  Nutr Metab (Lond)       Date:  2010-03-12       Impact factor: 4.169

6.  Role of NF-kappaB-dependent caveolin-1 expression in the mechanism of increased endothelial permeability induced by lipopolysaccharide.

Authors:  Chinnaswamy Tiruppathi; Jun Shimizu; Kayo Miyawaki-Shimizu; Stephen M Vogel; Angela M Bair; Richard D Minshall; Dan Predescu; Asrar B Malik
Journal:  J Biol Chem       Date:  2007-12-11       Impact factor: 5.157

7.  Inhibition of nitric oxide and inflammatory cytokines in LPS-stimulated murine macrophages by resveratrol, a potent proteasome inhibitor.

Authors:  Asaf A Qureshi; Xiu Qin Guan; Julia C Reis; Christopher J Papasian; Sandra Jabre; David C Morrison; Nilofer Qureshi
Journal:  Lipids Health Dis       Date:  2012-07-10       Impact factor: 3.876

8.  Inhibition of nitric oxide in LPS-stimulated macrophages of young and senescent mice by δ-tocotrienol and quercetin.

Authors:  Asaf A Qureshi; Xiaoyu Tan; Julia C Reis; Mostafa Z Badr; Christopher J Papasian; David C Morrison; Nilofer Qureshi
Journal:  Lipids Health Dis       Date:  2011-12-20       Impact factor: 3.876

Review 9.  Caveolin-1: an ambiguous partner in cell signalling and cancer.

Authors:  Andrew F G Quest; Jorge L Gutierrez-Pajares; Vicente A Torres
Journal:  J Cell Mol Med       Date:  2008-04-08       Impact factor: 5.310

10.  Crosstalk Between LXR and Caveolin-1 Signaling Supports Cholesterol Efflux and Anti-Inflammatory Pathways in Macrophages.

Authors:  Cristina M Ramírez; Marta Torrecilla-Parra; Virginia Pardo-Marqués; Mario Fernández de-Frutos; Ana Pérez-García; Carlos Tabraue; Juan Vladimir de la Rosa; Patricia Martín-Rodriguez; Mercedes Díaz-Sarmiento; Uxue Nuñez; Marta C Orizaola; Paqui G Través; Marta Camps; Lisardo Boscá; Antonio Castrillo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-27       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.